Regeneron Pharmaceuticals (REGN) Net Cash Flow (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Net Cash Flow of -$504.3 million for Q2 2026, up 53.21% year-over-year from -$329.2 million in Q2 2025, and down 231.34% quarter-over-quarter from -$152.2 million in Q1 2026.
Regeneron Pharmaceuticals (REGN) Net Cash Flow (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Net Cash Flow history runs 18 years deep, the most recent figure standing at -$504.3 million for Q2 2026.
- In Q2 2026, Net Cash Flow rose 53.21% year-over-year to -$504.3 million; the TTM figure through Jun 2026 stood at $452.3 million (up 424.1% YoY), while the FY2025 annual figure was $634.4 million, up 355.7% from the prior year.
- Net Cash Flow for Q2 2026 stood at -$504.3 million, down from -$152.2 million in the prior quarter.
- The five-year high for Net Cash Flow was $809.4 million in Q1 2023, with the low at -$2.0 billion in Q2 2023.
- The 5-year median for Net Cash Flow is $89.5 million (2022), against an average of -$23.9 million.
- The sharpest annual moves came in 2023 and 2025: Net Cash Flow slumped 4105.47% in 2023, then soared 573.25% in 2025.
- Regeneron Pharmaceuticals' Net Cash Flow stood at -$385.4 million in 2022, then surged by 249.82% to $577.4 million in 2023, then decreased by 17.23% to $477.9 million in 2024, then grew by 27.83% to $610.9 million in 2025, then plunged by 182.55% to -$504.3 million in 2026.
- Business Quant data shows REGN's Net Cash Flow at -$504.3 million in Q2 2026, -$152.2 million in Q1 2026, and $610.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -170.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -504.30 Mn |
| Jun 30, 2026 | -504.30 Mn |
| Mar 31, 2026 | -152.20 Mn |
| Mar 31, 2026 | -152.20 Mn |
| Dec 31, 2025 | 610.90 Mn |
| Dec 31, 2025 | 610.90 Mn |
| Sep 30, 2025 | 497.90 Mn |
| Sep 30, 2025 | 497.90 Mn |
| Jun 30, 2025 | -1.08 Bn |
| Jun 30, 2025 | -1.08 Bn |
| Mar 31, 2025 | 603.40 Mn |
| Mar 31, 2025 | 603.40 Mn |
| Dec 31, 2024 | 477.90 Mn |
| Dec 31, 2024 | 477.90 Mn |
| Sep 30, 2024 | 82.80 Mn |
| Sep 30, 2024 | 82.80 Mn |
| Jun 30, 2024 | -681.30 Mn |
| Jun 30, 2024 | -681.30 Mn |
| Mar 31, 2024 | -127.50 Mn |
| Mar 31, 2024 | -127.50 Mn |